Pulmonary Arterial Hypertension in Eastern Europe

Case Study

About the Case Study

Allucent was selected to provide development services for a Phase III study, which was designed to address the efficacy and safety of a compound for pulmonary arterial hypertension patients.  This study originally required 670 patients across the globe, but the enrollment was later increased to 1,150 due to study design changes.  Allucent played an integral part in the enrollment of the additional patients, providing 45% more patients than originally tasked. 

 

Study Overview:

Allucent was selected to provide development services for a Phase III study, which was designed to address the efficacy and safety of a compound for pulmonary arterial hypertension patients. This study originally required 670 patients across the globe, but the enrollment was later increased to 1,150 due to study design changes. Allucent played an integral part in the enrollment of the additional patients, providing 45% more patients than originally tasked.



DOWNLOAD RESOURCE